E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10049416 |
E.1.2 | Term | Short-bowel syndrome |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To evaluate the safety of the 1.25 mg formulation of teduglutide in Japanese pediatric participants with short bowel syndrome (SBS) who are dependent on parenteral support (PS), aged 4 months (corrected gestational age) or older, and requiring the dosing of 1.25 mg formulation. |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the efficacy of the 1.25 mg formulation of teduglutide in Japanese pediatric participants with SBS who are dependent on PS, aged 4 months (corrected gestational age) or older, and requiring the dosing of 1.25 mg formulation. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female pediatric participant of corrected gestational age 4 months or older. 2. Body weight at the time of screening and baseline visits of at least 5 kg and <10 kg for participants with normal renal function or mild renal impairment (estimated glomerular filtration rate >=50 milliliters [mL]/ minute [min]/1.73 meter [m]^2), OR at least 10 kg and <20 kg for participants with moderate or greater renal impairment (estimated glomerular filtration rate <50 mL/min/1.73 m^2). 3. Diagnosis of SBS with intestinal failure, defined as dependence on PS to provide at least 30% of fluid or caloric needs. 4. Participants to have stable PS for at least 1 month prior to screening as assessed by the investigator. Stable PS is defined as inability to significantly reduce parenteral nutrition/intravenous fluid (PN/IV) support, usually associated with minimal or no advance in enteral feeds (i.e., 10% or less change in PN or advance in feeds), assessed by the investigator. |
|
E.4 | Principal exclusion criteria |
1. A parent/guardian who is not capable of understanding or not willing to adhere to the study visit schedule and other protocol requirements. 2. Clinically significant intestinal obstruction, active or recurrent pancreatic or biliary disease, or dysmotility that prevents the advancement of enteral intake. 3. Intestinal malabsorption due to a genetic condition, such as cystic fibrosis, microvillus inclusion disease, etc. 4. Severe, known dysmotility syndrome, such as pseudo-obstruction or persistent, severe, active gastroschisis-related dysmotility, that is the primary contributing factor to feeding intolerance and inability to reduce PS, prior to screening. Dysmotility is defined as severe if it is expected to limit the advancement of enteral feeding. 5. Major GI surgical intervention including significant intestinal resection or bowel lengthening procedure within 3 months prior to screening (insertion of feeding tube, anastomotic ulcer repair, minor intestinal resections =<10 cm and endoscopic procedures are allowed). 6. Cardiac disease that makes the patient vulnerable to changes in fluid status. 7. History of cancer or known cancer predisposition syndrome, such as juvenile polyposis or Beckwith-Wiedemann syndrome, or first degree relative with early onset of GI cancer (including hepatobiliary and pancreatic cancer). 8. Concurrent treatment with GLP-2, human growth hormone, or analogs of these hormones within 6 months prior to the screening visit, or concurrent treatment with octreotide, or GLP-1 analogs within 30 days prior to the screening visit. 9. Concurrent treatment with biological therapy (eg, anti-tumor necrosis factor [anti-TNF]) for active Crohn's disease within 6 months prior to the screening visit. 10. Participation in a clinical study using an experimental drug (other than glutamine or omegaven) within 3 months or 5.5 half-lives of the experimental drug, whichever is longer, prior to the screening visit and for the duration of the study. 11. Known or suspected intolerance or hypersensitivity to the study drug, closely related compounds, or any of the stated ingredients. 12. Signs of active, severe, or unstable clinically significant hepatic impairment during the screening period as meeting at least 2 of any of the following parameters: a. International normalized ratio >1.5 not corrected with parenteral vitamin K b. Platelet count <100×10^3/microliter (µL) due to portal hypertension c. Presence of clinically significant gastric or esophageal varices d. Cirrhosis e. Persistent cholestasis defined as conjugated bilirubin >4 milligrams per deciliter (mg/dL) (>68 micromoles per liter [µmol/L]) over a 2-week period during screening f. Total bilirubin >=2x upper limit of normal (ULN) g. Aspartate aminotransferase (AST) >=3x ULN h. Alanine aminotransferase (ALT) >=3x ULN |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) 2. Number of Participants With Serious Adverse Events (SAEs) 3. Number of Participants With Adverse Events of Special Interest (AESIs) 4. Number of Participants With Clinically Significant Abnormalities in Vital Signs Reported as an Adverse Event 5. Change From Baseline in Z-Score of Body Weight 6. Change From Baseline in Z-Score of Height 7. Change From Baseline in Z-Score of Head Circumference 8. Change From Baseline in Z-Score of Weight-for-Length 9. Number of Participants With Clinically Significant Laboratory Safety Data Reported as an Adverse Event 10. Number of Participants With Significant Change in Urine Output Reported as an Adverse Event 11. Number of Participants With Significant Change in Stool Output Reported as an Adverse Event |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Up to Week 28 (end of study [EOS]) |
|
E.5.2 | Secondary end point(s) |
1. Change From Baseline in PS Volume 2. Percent Change From Baseline in PS Volume 3. Number of Participants who Demonstrate at least 20 Percent (%) Reduction From Baseline in PS Volume 4. Number of Participants who Achieved Enteral Autonomy 5. Change in Days per Week of PS |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 27 |